{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:47:36Z","timestamp":1792716456266,"version":"4.5.0"},"reference-count":63,"publisher":"Wiley","issue":"S8","license":[{"start":{"date-parts":[[2012,4,6]],"date-time":"2012-04-06T00:00:00Z","timestamp":1333670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chemotherapy\u2010induced peripheral neuropathy (CIPN) results from damage to or dysfunction of the peripheral nerves. The development of CIPN is anticipated for the majority of breast cancer patients who receive neurotoxic chemotherapy, depending on the agent used, dose, and schedule. Sensory symptoms often predominate and include numbness, tingling, and distal extremity pain. Weakness, gait impairment, loss of functional abilities, and other deficits may develop with more severe CIPN. This article outlines a prospective surveillance model for physical rehabilitation of women with breast cancer who develop CIPN. Rehabilitative efforts for CIPN start at the time of breast cancer diagnosis and treatment planning. The prechemotherapy evaluation identifies patients with preexisting peripheral nervous system disorders that may place them at higher risk for the development of CIPN. This clinical evaluation should include a history focusing on symptoms and functional activities as well as a physical examination that objectively assesses the patient's strength, sensation, reflexes, and gait. Ongoing surveillance following the initiation of a neurotoxic agent is important to monitor for the development and progression of symptoms associated with CIPN, and to ensure its resolution over the long term. CIPN is managed best by a multidisciplinary team approach. Early identification of symptoms will ensure appropriate referral and timely symptom management. The prospective surveillance model promotes a patient\u2010centered approach to care, from pretreatment through survivorship and palliative care. In this way, the model offers promise in addressing and minimizing both the acute and long\u2010term morbidity associated with CIPN. Cancer 2012;. \u00a9 2012 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.27463","type":"journal-article","created":{"date-parts":[[2012,4,6]],"date-time":"2012-04-06T08:39:42Z","timestamp":1333701582000},"page":"2250-2260","source":"Crossref","is-referenced-by-count":86,"title":["A prospective surveillance model for physical rehabilitation of women with breast cancer"],"prefix":"10.1002","volume":"118","author":[{"given":"Michael D.","family":"Stubblefield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"McNeely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,6]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"HowladerN NooneAM KrapchoM et al. SEER Cancer Statistics Review 1975\u20132008. National Cancer Institute: Bethesda MD.http:\/\/seer.cancer.gov\/csr\/1975_2008\/. Based on November 2010 SEER data submission posted to the SEER Web site 2011."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0078"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-010-0108-3"},{"key":"e_1_2_6_5_2","first-page":"398","article-title":"Chemotherapy\u2010induced peripheral neuropathy: a need for standardization in measurement","volume":"4","author":"Dunlap B","year":"2006","journal-title":"J Support Oncol."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2009.03.013"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cnd.0000211401.19995.a2"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2011.0016"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-010-0773-6"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3233\/BD-2010-0304","article-title":"Current treatment options in triple negative breast cancer","volume":"32","author":"Rodler E","year":"2010","journal-title":"Breast Dis."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0887-8"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.10.1832"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2005.11.014"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.01.017"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1993.1287"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410350310"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.8.1232"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880601)61:11<2192::AID-CNCR2820611110>3.0.CO;2-A"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.7.1261"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1165"},{"key":"e_1_2_6_21_2","first-page":"1171","article-title":"Phase I trial of taxol in patients with advanced cancer","volume":"71","author":"Donehower RC","year":"1987","journal-title":"Cancer Treat Rep."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.0543"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2011.03.006"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2009.04.006"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)61474-2"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.62.4.310"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16508-2"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/17453679508995574"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-002-0036-y"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-011-0114-0"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21226"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.12.008"},{"key":"e_1_2_6_33_2","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010\u201306\u201014_QuickReference_8.5x11.pdf."},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20090405"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1188\/08.CJON.243-247"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1188\/07.CJON.901-913"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1188\/07.CJON.361-376"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2011.03.008"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2011.03.008"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2010.03.021"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.03.022"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2007.05.007"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14157"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1127-7"},{"key":"e_1_2_6_45_2","unstructured":"2007 Scientific Foundations and Principles of Practice in Musculoskeletal Rehabilitation Philadelphia PA TL Chmielewski TE Hewett WJ Hurd L Snyder\u2010Mackler DJ Magee JE Zachazewski WS Quillen Principles of neuromuscular control for injury prevention and rehabilitation 375 387"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1188\/05.CJON.189-193"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1053\/apmr.2001.19742"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52155.x"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120018236"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.10.010"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0782-4"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2005.07.005"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12156-010-0044-1"},{"key":"e_1_2_6_54_2","unstructured":"2009 ACSM's Resources for Clinical Exercise Physiology: Musculoskeletal Neuromuscular Neoplastic Immunologic and Hematologic Conditions Baltimore MD MT Pfefer J Myers D Nieman Peripheral neuropathy and neuropathic pain 104 112"},{"key":"e_1_2_6_55_2","first-page":"CD003904","article-title":"Exercise for people with peripheral neuropathy","volume":"4","author":"White CM","year":"2004","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.051073"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/aim.24.2.87"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4741.2010.01056.x"},{"key":"e_1_2_6_59_2","first-page":"259","article-title":"Primary care and communication in shared cancer care: a qualitative study","volume":"17","author":"Sada YH","year":"2011","journal-title":"Am J Manag Care."},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-011-0185-7"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-010-0165-3"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8575"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2011.03.010"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01512.x"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.27463","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.27463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:32:23Z","timestamp":1760290343000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.27463"}},"subtitle":["Chemotherapy\u2010induced peripheral neuropathy"],"short-title":[],"issued":{"date-parts":[[2012,4,6]]},"references-count":63,"journal-issue":{"issue":"S8","published-print":{"date-parts":[[2012,4,15]]}},"alternative-id":["10.1002\/cncr.27463"],"URL":"https:\/\/doi.org\/10.1002\/cncr.27463","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,6]]}}}